Tribune Web Desk
Chandigarh, May 13
National regulator Drugs Controller General of India (DCGI) has accepted the recommendation of the Subject Expert Committee (SEC) and accorded permission to conduct the phase-II/III clinical trials of Covaxin in the age group 2 to 18 years.
Covaxin manufacturer Bharat Biotech had proposed to carry out the trial, which will be conducted on 525 healthy volunteers.
In the trial, the vaccine will be given by intramuscular route in two doses at day 0 and day 28.
As rapid regulatory response, the proposal was deliberated by the SEC on May 11.
Twitter has lost its status as an intermediary platform in I...
In a video uploaded on social media, elderly Muslim man had ...
Recovery rate improves to 95.93 per cent
The pilot, to test cold storage at minus 18 degrees, and oth...
Says 50% judges should sit on alternate days to hear persons...